These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 23959051)

  • 1. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
    Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
    Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection?
    Robinson KA; Pockaj BA; Wasif N; Kaufman K; Gray RJ
    Am J Surg; 2014 Dec; 208(6):1060-4; discussion 1063-4. PubMed ID: 25312842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
    Weiss A; Mittendorf EA; DeSnyder SM; Hwang RF; Bea V; Bedrosian I; Hoffman K; Adrade B; Sahin AA; Kuerer HM; Hunt KK; Caudle AS
    Clin Breast Cancer; 2018 Aug; 18(4):276-281. PubMed ID: 29100726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the axilla: has Z0011 had an impact?
    Joyce DP; Lowery AJ; McGrath-Soo LB; Downey E; Kelly L; O'Donoghue GT; Barry M; Hill AD
    Ir J Med Sci; 2016 Feb; 185(1):145-9. PubMed ID: 25595827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of Applying ACOSOG Z0011 Criteria in the Axillary Management of Invasive Lobular Carcinoma: A Multi-institutional Cohort Study.
    Roberts A; Nofech-Mozes S; Youngson B; McCready DR; Al-Assi M; Ramkumar S; Cil T
    Ann Surg Oncol; 2015 Oct; 22(10):3397-401. PubMed ID: 26215196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
    Shah-Khan M; Boughey JC
    Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study.
    Peng Y; Liu M; Li X; Tong F; Cao Y; Liu P; Zhou B; Liu H; Cheng L; Guo J; Xie F; Yang H; Wang S; Wang C; Chen Y; Wang S
    World J Surg Oncol; 2021 Apr; 19(1):128. PubMed ID: 33879180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Costs Reduced After Incorporating the Results of the American College of Surgeons Oncology Group Z0011 Trial into Clinical Practice.
    Fillion MM; Glass KE; Hayek J; Wehr A; Phillips G; Terando A; Agnese DM
    Breast J; 2017 May; 23(3):275-281. PubMed ID: 27900818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
    Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
    Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
    Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
    Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011.
    Ong CT; Thomas SM; Blitzblau RC; Fayanju OM; Park TS; Plichta JK; Rosenberger LH; Hyslop T; Shelley Hwang E; Greenup RA
    Ann Surg Oncol; 2017 Nov; 24(12):3559-3566. PubMed ID: 28879416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of survival outcomes between axillary conservation and axillary lymph node dissections in N1 early breast cancer: a propensity-matched SEER analysis.
    Wu N; Su X; Tan Q; Luo J; Yuan Y; Hou L; Li J
    Clin Transl Oncol; 2023 Apr; 25(4):1091-1101. PubMed ID: 36515887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
    Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
    Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial: An institutional review.
    Le VH; Brant KN; Blackhurst DW; Schammel CM; Schammel DP; Cornett WR; McKinley BP
    Breast; 2016 Oct; 29():117-9. PubMed ID: 27479042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.